Immunoregulatory role of miR-155 in cholestatic liver diseases: implications for primary biliary cholangitis and primary sclerosing cholangitis associated with ulcerative colitis

Alicja Łaba, Wiesława Rogoza-Mateja, Agnieszka Kempińska-Podhorodecka

Abstract


Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are chronic cholestatic liver diseases characterised by progressive bile duct injury, persistent cholestasis, fibrosis and eventual cirrhosis. Growing evidence indicates that epigenetic mechanisms, particularly microRNAs, play an important role in their pathogenesis. Among them, microRNA-155 (miR-155) has emerged as a central immunoregulatory molecule involved in both innate and adaptive immune responses. MicroRNA-155 regulates key inflammatory signalling pathways, including NF-κB and Janus kinase (JAK)/STAT, and interferes with bile acid homeostasis through suppression of the farnesoid X receptor, thereby contributing to sustained cholestasis and inflammatory injury. Increased expression of miR-155 has been observed in liver tissue, serum and peripheral blood mononuclear cells of patients with PBC and PSC, reflecting local and systemic immune activation. Importantly, miR-155 also links chronic inflammation with impairment of the mismatch repair system and microsatellite instability, promoting colorectal carcinogenesis in patients with PSC associated with ulcerative colitis. This review summarises the biogenesis, regulation and pathogenic significance of miR-155 in PBC and PSC, with particular emphasis on its role in mismatch repair dysfunction and emerging therapeutic implications.

Keywords


miR-155; cholestatic liver disease; primary sclerosing cholangitis; primary biliary cholangitis; ulcerative colitis

Full Text:

PDF

References


Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol 2020;17(2):93-110.

Lv T, Chen S, Li M, Zhang D, Kong Y, Jia J. Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36(6):1423-34.

Houri I, Hirschfield GM. Primary Biliary Cholangitis: Pathophysiology. Clin Liver Dis 2024;28(1):79-92.

European Association for the Study of the L. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017;67(1):145-72.

Walker JG, Doniach D, Roitt IM, Sherlock S. Serological Tests in Diagnosis of Primary Biliary Cirrhosis. Lancet 1965;1(7390):827-31.

Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, et al. Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’. Gastroenterology 2015;149(6):1627-9.

Hirschfield GM, Gershwin ME. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol 2013;8:303-30.

Hirschfield GM, Beuers U, Kupcinskas L, Ott P, Bergquist A, Farkkila M, et al. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. J Hepatol 2021;74(2):321-9.

Kowdley KV, Luketic V, Chapman R, Hirschfield GM, Poupon R, Schramm C, et al. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology 2018;67(5):1890-902.

Kowdley KV, Vuppalanchi R, Levy C, Floreani A, Andreone P, LaRusso NF, et al. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. J Hepatol 2020;73(1):94-101.

Schattenberg JM, Pares A, Kowdley KV, Heneghan MA, Caldwell S, Pratt D, et al. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol 2021;74(6):1344-54.

Floreani A, Gabbia D, De Martin S. Obeticholic Acid for Primary Biliary Cholangitis. Biomedicines 2022;10(10):2464.

Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet 2013;382(9904):1587-99.

Trivedi PJ, Hirschfield GM. Recent advances in clinical practice: epidemiology of autoimmune liver diseases. Gut 2021;70(10):1989-2003.

Molodecky NA, Kareemi H, Parab R, Barkema HW, Quan H, Myers RP, et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology 2011;53(5):1590-9.

Song J, Li Y, Bowlus CL, Yang G, Leung PSC, Gershwin ME. Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review. Clin Rev Allergy Immunol 2020;58(1):134-49.

Wunsch E, Milkiewicz M, Norman GL, Laba A, Kruk B, Milkiewicz P. Prognostic significance of anti-gliadin and anti-F-actin immunoglobulin A antibodies in primary sclerosing cholangitis. Pol Arch Intern Med 2025;135(1):16910.

Rossi RE, Conte D, Massironi S. Primary sclerosing cholangitis associated with inflammatory bowel disease: an update. Eur J Gastroenterol Hepatol 2016;28(2):123-31.

Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002;56(1):48-54.

Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009;50(1):158-64.

Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116(2):281-97.

O’Connell RM, Kahn D, Gibson WS, Round JL, Scholz RL, Chaudhuri AA, et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 2010;33(4):607-19.

Tam W. Identification and characterization of human BIC, a gene on chromosome 21 that encodes a noncoding RNA. Gene 2001;274(1-2):157-67.

Mahesh G, Biswas R. MicroRNA-155: A Master Regulator of Inflammation. J Interferon Cytokine Res 2019;39(6):321-30.

Huffaker TB, O’Connell RM. miR-155-SOCS1 as a Functional Axis: Satisfying the Burden of Proof. Immunity 2015;43(1):3-4.

Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 2001;293(5531):834-8.

O’Connell RM, Rao DS, Baltimore D. microRNA regulation of inflammatory responses. Annu Rev Immunol 2012;30:295-312.

Hu R, Huffaker TB, Kagele DA, Runtsch MC, Bake E, Chaudhuri AA, et al. MicroRNA-155 confers encephalogenic potential to Th17 cells by promoting effector gene expression. J Immunol 2013;190(12):5972-80.

Quinn SR, Mangan NE, Caffrey BE, Gantier MP, Williams BR, Hertzog PJ, et al. The role of Ets2 transcription factor in the induction of microRNA-155 (miR-155) by lipopolysaccharide and its targeting by interleukin-10. J Biol Chem 2014;289(7):4316-25.

McCoy CE, Sheedy FJ, Qualls JE, Doyle SL, Quinn SR, Murray PJ, et al. IL-10 inhibits miR-155 induction by toll-like receptors. J Biol Chem 2010;285(27):20492-8.

Bruning U, Cerone L, Neufeld Z, Fitzpatrick SF, Cheong A, Scholz CC, et al. MicroRNA-155 promotes resolution of hypoxia-inducible factor 1alpha activity during prolonged hypoxia. Mol Cell Biol 2011;31(19):4087-96.

Wan G, Xie W, Liu Z, Xu W, Lao Y, Huang N, et al. Hypoxia-induced MIR155 is a potent autophagy inducer by targeting multiple players in the MTOR pathway. Autophagy 2014;10(1):70-9.

Amado T, Schmolka N, Metwally H, Silva-Santos B, Gomes AQ. Cross-regulation between cytokine and microRNA pathways in T cells. Eur J Immunol 2015;45(6):1584-95.

Huang J, Xu X, Yang J. miRNAs Alter T Helper 17 Cell Fate in the Pathogenesis of Autoimmune Diseases. Front Immunol 2021;12:593473.

Isac T, Isac S, Rababoc R, Cotorogea M, Iliescu L. Epigenetics in inflammatory liver diseases: A clinical perspective (review). Exp Ther Med 2022;23(5):366.

Revilla-Nuin B, de Bejar A, Martinez-Alarcon L, Herrero JI, Martinez-Caceres CM, Ramirez P, et al. Differential profile of activated regulatory T cell subsets and microRNAs in tolerant liver transplant recipients. Liver Transpl 2017;23(7):933-45.

Liu R, Li Y, Zheng Q, Ding M, Zhou H, Li X. Epigenetic modification in liver fibrosis: Promising therapeutic direction with significant challenges ahead. Acta Pharm Sin B 2024;14(3):1009-29.

O’Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 2007;104(5):1604-9.

Fu Q, Zhu X, Fang Q, Han H, Wang Z, Xie J, et al. miR-155 enhances apoptosis of macrophage through suppressing PI3K-AKT activation in Pseudomonas aeruginosa keratitis. Heliyon 2024;10(17):e36585.

Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, et al. Regulation of the germinal center response by microRNA-155. Science 2007;316(5824):604-8.

Teng G, Hakimpour P, Landgraf P, Rice A, Tuschl T, Casellas R, et al. MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity 2008;28(5):621-9.

Vigorito E, Perks KL, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S, et al. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 2007;27(6):847-59.

Rai D, Kim SW, McKeller MR, Dahia PL, Aguiar RC. Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc Natl Acad Sci USA 2010;107(7):3111-6.

Fu X, Wen H, Jing L, Yang Y, Wang W, Liang X, et al. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway. Cancer Sci 2017;108(4):620-31.

O’Connell RM, Chaudhuri AA, Rao DS, Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci USA 2009;106(17):7113-8.

Bi J, Liu J, Chen X, Shi N, Wu H, Tang H, et al. MiR-155-5p-SOCS1/JAK1/STAT1 participates in hepatic lymphangiogenesis in liver fibrosis and cirrhosis by regulating M1 macrophage polarization. Hum Exp Toxicol 2023;42:9603271221141695.

Bala S, Zhuang Y, Nagesh PT, Catalano D, Zivny A, Wang Y, et al. Therapeutic inhibition of miR-155 attenuates liver fibrosis via STAT3 signaling. Mol Ther Nucleic Acids 2023;33:413-27.

Louafi F, Martinez-Nunez RT, Sanchez-Elsner T. MicroRNA-155 targets SMAD2 and modulates the response of macrophages to transforming growth factor-beta. J Biol Chem 2010;285(53):41328-36.

Bala S, Csak T, Saha B, Zatsiorsky J, Kodys K, Catalano D, et al. The pro-inflammatory effects of miR-155 promote liver fibrosis and alcohol-induced steatohepatitis. J Hepatol 2016;64(6):1378-87.

Jun Hu XC. miR-155 modulates fatty acid accumulation by targeting C/EBPβ in free fatty acid-induced steatosis in HepG2 cells. Non-coding RNA Investig 2019;3:10.

Bala S, Marcos M, Kodys K, Csak T, Catalano D, Mandrekar P, et al. Up-regulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor alpha (TNFalpha) production via increased mRNA half-life in alcoholic liver disease. J Biol Chem 2011;286(2):1436-44.

Shen M, Pan H, Ke J, Zhao F. NF-kappaB-upregulated miR-155-5p promotes hepatocyte mitochondrial dysfunction to accelerate the development of nonalcoholic fatty liver disease through downregulation of STC1. J Biochem Mol Toxicol 2022;36(6):e23025.

Padgett KA, Lan RY, Leung PC, Lleo A, Dawson K, Pfeiff J, et al. Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J Autoimmun 2009;32(3-4):246-53.

Adamowicz M, Kempinska-Podhorodecka A, Abramczyk J, Banales JM, Milkiewicz P, Milkiewicz M. Suppression of Hepatic PPARalpha in Primary Biliary Cholangitis Is Modulated by miR-155. Cells 2022;11(18):2880.

Rodrigues PM, Perugorria MJ, Santos-Laso A, Bujanda L, Beuers U, Banales JM. Primary biliary cholangitis: A tale of epigenetically-induced secretory failure? J Hepatol 2018;69(6):1371-83.

Zou F, Wang S, Xu M, Wu Z, Deng F. The role of sphingosine-1-phosphate in the gut mucosal microenvironment and inflammatory bowel diseases. Front Physiol 2023;14:1235656.

Pasca S, Jurj A, Petrushev B, Tomuleasa C, Matei D. MicroRNA-155 Implication in M1 Polarization and the Impact in Inflammatory Diseases. Front Immunol 2020;11:625.

Bala S, Csak T, Kodys K, Catalano D, Ambade A, Furi I, et al. Alcohol-induced miR-155 and HDAC11 inhibit negative regulators of the TLR4 pathway and lead to increased LPS responsiveness of Kupffer cells in alcoholic liver disease. J Leukoc Biol 2017;102(2):487-98.

Jouve M, Carpentier R, Kraiem S, Legrand N, Sobolewski C. MiRNAs in Alcohol-Related Liver Diseases and Hepatocellular Carcinoma: A Step toward New Therapeutic Approaches? Cancers (Basel) 2023;15(23):5557.

Alivernini S, Gremese E, McSharry C, Tolusso B, Ferraccioli G, McInnes IB, et al. MicroRNA-155-at the Critical Interface of Innate and Adaptive Immunity in Arthritis. Front Immunol 2017;8:1932.

Chen M, Wang F, Xia H, Yao S. MicroRNA-155: Regulation of Immune Cells in Sepsis. Mediators Inflamm 2021;2021:8874854.

Zhang L, Wang W, Li X, He S, Yao J, Wang X, et al. MicroRNA-155 promotes tumor growth of human hepatocellular carcinoma by targeting ARID2. Int J Oncol 2016;48(6):2425-34.

Ichim C, Boicean A, Anderco P, Todor SB, Hasegan A, Birsan S, et al. MicroRNAs in Liver Cirrhosis: Diagnostic and Therapeutic Perspectives – A Comprehensive Review. J Pers Med 2025;15(8):376.

Kempinska-Podhorodecka A, Milkiewicz M, Wasik U, Ligocka J, Zawadzki M, Krawczyk M, et al. Decreased Expression of Vitamin D Receptor Affects an Immune Response in Primary Biliary Cholangitis via the VDR-miRNA155--SOCS1 Pathway. Int J Mol Sci 2017;18(2):289.

Abenavoli L, Procopio AC, Fagoonee S, Pellicano R, Carbone M, Luzza F, et al. Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists. Diseases 2020;8(2):20.

Beuers U, Trauner M, Jansen P, Poupon R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 2015;62(1 Suppl):S25-37.

Pellicciari R, Costantino G, Fiorucci S. Farnesoid X receptor: from structure to potential clinical applications. J Med Chem 2005;48(17):5383-403.

Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, et al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med 2016;375(7):631-43.

Bala S, Petrasek J, Mundkur S, Catalano D, Levin I, Ward J, et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 2012;56(5):1946-57.

Torres J, Pineton de Chambrun G, Itzkowitz S, Sachar DB, Colombel JF. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther 2011;34(5):497-508.

Claessen MM, Lutgens MW, van Buuren HR, Oldenburg B, Stokkers PC, van der Woude CJ, et al. More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis 2009;15(9):1331-6.

Boonstra K, van Erpecum KJ, van Nieuwkerk KM, Drenth JP, Poen AC, Witteman BJ, et al. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis 2012;18(12):2270-6.

Broome U, Lindberg G, Lofberg R. Primary sclerosing cholangitis in ulcerative colitis – a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology 1992;102(6):1877-80.

Cornillet M, Geanon D, Bergquist A, Bjorkstrom NK. Immunobiology of primary sclerosing cholangitis. Hepatology 2025;82(4):911-26.

Bromke MA, Krzystek-Korpacka M. Bile Acid Signaling in Inflammatory Bowel Disease. Int J Mol Sci 2021;22(16):9096.

Santos AA, Pires D, Marques V, Alesina N, Herraez E, Roudnicky P, et al. Primary bile acid shapes peripheral immunity in inflammatory bowel disease-associated primary sclerosing cholangitis. Clin Sci (Lond) 2025;138(12):703-16.

Adamowicz M, Stukan I, Milkiewicz P, Bialek A, Milkiewicz M, Kempinska-Podhorodecka A. Modulation of Mismatch Repair and the SOCS1/p53 Axis by microRNA-155 in the Colon of Patients with Primary Sclerosing Cholangitis. Int J Mol Sci 2022;23(9):4905.

Kempinska-Podhorodecka A, Abramczyk J, Cielica E, Hula B, Maciejowska H, Banales J, et al. Effect of Low Testosterone Levels on the Expression of Proliferator-Activated Receptor Alpha in Female Patients with Primary Biliary Cholangitis. Cells 2023;12(18):2273.

Valeri N, Gasparini P, Fabbri M, Braconi C, Veronese A, Lovat F, et al. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci USA 2010;107(15):6982-7.

Kempinska-Podhorodecka A, Adamowicz M, Ostrycharz E, Chmielarz M, Wojcicki M, Milkiewicz P, et al. Role of miR-506 in ulcerative colitis associated with primary sclerosing cholangitis. Sci Rep 2021;11(1):10134.

Singh UP, Murphy AE, Enos RT, Shamran HA, Singh NP, Guan H, et al. miR-155 deficiency protects mice from experimental colitis by reducing T helper type 1/type 17 responses. Immunology 2014;143(3):478-89.

Min M, Peng L, Yang Y, Guo M, Wang W, Sun G. MicroRNA-155 is involved in the pathogenesis of ulcerative colitis by targeting FOXO3a. Inflamm Bowel Dis 2014;20(4):652-9.

Al-Haidari A, Algaber A, Madhi R, Syk I, Thorlacius H. MiR-155-5p controls colon cancer cell migration via post-transcriptional regulation of Human Antigen R (HuR). Cancer Lett 2018;421:145-51.

Ye J, Guo R, Shi Y, Qi F, Guo C, Yang L. miR-155 Regulated Inflammation Response by the SOCS1-STAT3-PDCD4 Axis in Atherogenesis. Mediators Inflamm 2016;2016:8060182.

Reshetnyak VI. Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis. World J Gastroenterol 2015;21(25):7683-708.

Moutabian H, Radi UK, Saleman AY, Adil M, Zabibah RS, Chaitanya MNL, et al. MicroRNA-155 and cancer metastasis: Regulation of invasion, migration, and epithelial-to-mesenchymal transition. Pathol Res Pract 2023;250:154789.

Anastasiadou E, Seto AG, Beatty X, Hermreck M, Gilles ME, Stroopinsky D, et al. Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo. Clin Cancer Res 2021;27(4):1139-49.

Adamowicz M, Abramczyk J, Kilanczyk E, Milkiewicz P, Laba A, Milkiewicz M, et al. Modulation of miR-155-5p signalling via 5-ASA for the prevention of high microsatellite instability: an in vitro study using human epithelial cell lines. J Physiol Biochem 2024;80(3):573-83.

Adamowicz M, Milkiewicz P, Kempinska-Podhorodecka A. 5-aminosalicylic acid inhibits the expression of oncomiRs and pro-inflammatory microRNAs: an in vitro study. J Physiol Pharmacol 2021;72(4):529-35.

Christofides A, Konstantinidou E, Jani C, Boussiotis VA. The role of peroxisome proliferator-activated receptors (PPAR) in immune responses. Metabolism 2021;114:154338.




DOI: https://doi.org/10.21164/pomjlifesci.1207

Copyright (c) 2025 Alicja Łaba, Wiesława Rogoza-Mateja, Agnieszka Kempińska-Podhorodecka

License URL: https://creativecommons.org/licenses/by-nc-nd/3.0/pl/